<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peroxisomal disorders</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peroxisomal disorders</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Peroxisomal disorders</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald JA Wanders, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism caused by impairment in the biogenesis of peroxisomes or one of their metabolic functions. In most cases, this results in neurologic dysfunction of varying extent.</p><p>The major peroxisomal disorders will be reviewed here. The most common peroxisomal disorder, X-linked adrenoleukodystrophy, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Various classification schemas have been proposed for peroxisomal disorders. In general, they can be classified according to the pathologic mechanism or the clinical characteristics.</p><p class="headingAnchor" id="H1829707879"><span class="h2">Classification by mechanism</span><span class="headingEndMark"> — </span>Peroxisomal disorders are divided into two major categories depending upon whether the defect is in the biogenesis of peroxisomes or a single peroxisomal enzyme deficiency  (<a class="graphic graphic_table graphicRef74261" href="/z/d/graphic/74261.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]. More recently, a third category has been described (disorders of peroxisome division); however, disorders in this category are exceedingly rare [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peroxisome biogenesis disorders (PBD)</strong> – The PBD group is subdivided into two distinct subgroups including: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Zellweger spectrum disorders (ZSD) – In ZSD, there is a generalized loss of peroxisomal functions [<a href="#rid4">4</a>]. (See <a class="local">'Zellweger spectrum disorders'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rhizomelic chondrodysplasia punctata (RCDP) types 1 and 5 – In these disorders, peroxisomes are present, but they lack a specific group of proteins. (See <a class="local">'RCDP spectrum disorders'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single peroxisomal enzyme deficiencies</strong> – The following disorders are characterized by deficiency of a single peroxisomal enzyme; peroxisome biogenesis is intact in these disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACBD5 (acyl-CoA-binding domain type 5) deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F618863&amp;token=tEpDslnpc0F0kICl%2Fz7sFbbHsBJVAXU52QtjSlxi7cW4rQeagFYU6rgL5XzlTalA&amp;TOPIC_ID=6147" target="_blank">MIM #618863</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>ACOX1 (acyl CoA oxidase-1) deficiency (see <a class="local">'ACOX1 and DBP deficiencies'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>ACOX2 deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617308&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz53tTiXgkurPAGWmjYG6XoW&amp;TOPIC_ID=6147" target="_blank">MIM #617308</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>AMACR (alpha-methylacyl-CoA racemase) deficiency (see <a class="local">'Other disorders'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>BAAT (bile acid-CoA: amino acid N-acyltransferase) deficiency (see <a class="local">'Other disorders'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>DBP (D-bifunctional protein) deficiency (see <a class="local">'ACOX1 and DBP deficiencies'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Glycolate oxidase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>PMP70 (peroxisomal membrane protein 70) deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F616278&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5%2FVq%2F3jIbp1st3Yzvrowkr&amp;TOPIC_ID=6147" target="_blank">MIM #616278</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Primary hyperoxaluria type 1 (alanine glyoxylate aminotransferase deficiency) (see  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>RCDP types 2, 3, and 4 (see <a class="local">'RCDP spectrum disorders'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Refsum disease (phytanoyl CoA hydroxylase deficiency)</p><p class="bulletIndent2"><span class="glyph">•</span>SCPX (sterol carrier protein X) deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613724&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5sIqshMICNREmg2U9JXQQQ&amp;TOPIC_ID=6147" target="_blank">MIM #613724</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>X-linked adrenoleukodystrophy (X-ALD) (see  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of peroxisome division</strong> – These are rare disorders caused by mutations in genes encoding proteins involved in peroxisome division (eg, <em>PEX11</em> beta, <em>DLP1/DNML1</em>, <em>MFF</em>, <em>GDAP1</em>) [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H2823526065"><span class="h2">Clinical classification</span><span class="headingEndMark"> — </span>Clinically, the peroxisomal disorders can be subdivided into six main groups, including  (<a class="graphic graphic_table graphicRef142994" href="/z/d/graphic/142994.html" rel="external">table 2</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebrohepatorenal syndromes</strong> – This category includes disorders that are characterized by variable degrees of liver and kidney involvement in conjunction with neurologic abnormalities, vision and hearing impairment, and craniofacial dysmorphisms. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Zellweger spectrum disorders (see <a class="local">'Zellweger spectrum disorders'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>ACOX1 deficiency (see <a class="local">'ACOX1 and DBP deficiencies'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>DBP deficiency (see <a class="local">'ACOX1 and DBP deficiencies'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhizomelic chondrodysplasias</strong> – This category includes RCDP types 1 to 5. The unique feature that distinguishes RDCPs from other peroxisomal disorders is pronounced short stature that primarily affects the proximal long bones (rhizomelia). Other clinical features include developmental delay, dysmorphic facies, congenital cataracts, ichthyosis, and joint contractures. (See <a class="local">'RCDP spectrum disorders'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refsum disease</strong> – Refsum disease is characterized by progressive vision loss and peripheral neuropathy. Unlike many other peroxisomal disorders, which often present in infancy or early childhood, Refsum disease typically presents in adolescence or early adulthood. (See <a class="local">'Refsum disease'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-ALD </strong>– The clinical spectrum of X-ALD is variable, as summarized in the table  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 3</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hyperoxaluria type 1 (PH1)</strong> – PH1 is characterized by recurrent kidney stones and chronic kidney disease. It is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other rare disorders</strong> – The fifth category consists of a group of rare disorders with variable features. Some of these disorders are newly recognized and the full spectrum of disease is still emerging. These include (see <a class="local">'Other disorders'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACBD5 deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>ACOX2 deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>AMACR deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>BAAT deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>SCPX deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>PMP70 deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Glycolate oxidase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Disorders of peroxisome division</p><p></p><p class="headingAnchor" id="H5"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Peroxisomal disorders occur in approximately 1 to 5 per 10,000 live births [<a href="#rid2">2</a>]. In one study, among 1000 patients with inborn errors of metabolism referred to a tertiary center between 1982 and 1997, peroxisomal disorders accounted for 3 percent [<a href="#rid5">5</a>].</p><p>X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Epidemiology'</a>.)</p><p>Zellweger syndrome is the most common peroxisomal disorder presenting in early infancy, with an estimated incidence of 1 to 4 per 100,000 live births [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Peroxisomes are subcellular organelles with a variable diameter ranging from 0.05 to 0.5 micron in diameter and are present in all cells except erythrocytes. The highest concentration of peroxisomes is in the liver and kidney [<a href="#rid7">7</a>]. Although long regarded as organelles of little physiologic significance, peroxisomes are now known to catalyze a number of different functions in cellular metabolism, which include the following [<a href="#rid8">8-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Catalytic functions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta-oxidation of very long chain fatty acids (VLCFA), pristanic acid, and long-chain dicarboxylic acids</p><p class="bulletIndent2"><span class="glyph">•</span>Alpha-oxidation of phytanic acid</p><p class="bulletIndent2"><span class="glyph">•</span>Oxidation of pipecolic acid</p><p class="bulletIndent2"><span class="glyph">•</span>Detoxification of glyoxylate</p><p class="bulletIndent2"><span class="glyph">•</span>Degradation of hydrogen peroxide by catalase</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anabolic functions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Synthesis of bile acids</p><p class="bulletIndent2"><span class="glyph">•</span>Synthesis of plasmalogens, which are important components of cell membranes and myelin</p><p class="bulletIndent2"><span class="glyph">•</span>Synthesis of certain polyunsaturated fatty acids (PUFAs), notably docosahexaenoic acid (C22:6).</p><p></p><p>The pathophysiology of the different peroxisomal disorders is complex:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zellweger spectrum disorder (ZSD)</strong> – In ZSD, there is a generalized loss of peroxisomal functions, caused by molecular defects in different genes coding for peroxins, which are proteins required for the proper biogenesis and maintenance of peroxisomes [<a href="#rid4">4</a>]. These defects interfere with the formation of pre-peroxisomal vesicles at the site of the endoplasmic reticulum, subsequent import of peroxisomal proteins into vesicles, and/or maintenance of peroxisomes [<a href="#rid4">4</a>]. (See <a class="local">'Zellweger spectrum disorders'</a> below.)</p><p></p><p class="bulletIndent1">In patients with ZSD who have isolated defects in the peroxisomal beta-oxidation system, the neuropathology appears to be related to cellular injury from metabolites that accumulate as a result of the deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhizomelic chondrodysplasia punctata (RCDP) type 1 </strong>– In type 1 RCDP, peroxisomes are present, but they lack a specific group of proteins due to mutations in one of the peroxisome biogenesis (PEX) genes (most commonly <em>PEX7</em>) [<a href="#rid11">11</a>]. This affects one of the two major import pathways for peroxisomal proteins into peroxisomes (ie, the PTS2-import pathway). As a consequence, several peroxisomal proteins targeted to peroxisomes via the PTS2-pathway are deficient. The result is impaired synthesis of ether phospholipids and the alpha-oxidation of phytanic acid. (See <a class="local">'RCDP spectrum disorders'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refsum disease</strong> – Accumulation of phytanic acid is the sole biochemical abnormality responsible for the physiologic consequences of Refsum disease. Phytanic acid is a branched-chain fatty acid derived from the <a class="drug drug_pediatric" data-topicid="118595" href="/z/d/drug information/118595.html" rel="external">chlorophyll</a> constituent phytol that is present in the typical human diet. Normally, phytanic acid is metabolized by activation to its CoA ester, phytanoyl-CoA, and then metabolized via alpha-oxidation to pristanic acid. Patients with Refsum disease are unable to degrade phytanic acid because of deficient activity of PAHX, a peroxisomal enzyme that catalyzes the first step of phytanic acid alpha-oxidation. The mechanism by which phytanic acid is toxic to neuronal and other tissues is uncertain. (See <a class="local">'Refsum disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACOX2 and AMACR deficiencies</strong> – In Acyl-CoA oxidase 2 (ACOX2) and alpha-methylacyl-CoA racemase (AMACR) deficiencies, bile acid synthesis is impaired. The resulting accumulation of bile acids intermediates cause early-onset liver disease as the dominant feature. Patients with AMACR deficiency may also develop late-onset progressive neurologic disease. (See <a class="local">'Other disorders'</a> below.)</p><p></p><p class="headingAnchor" id="H2257167954"><span class="h1">NEUROPATHOLOGY</span><span class="headingEndMark"> — </span>Mounting evidence implicates mitochondrial dysfunction as a potential trigger of both neurodevelopmental defects and neurodegeneration [<a href="#rid12">12</a>]. Accumulation of alpha-synuclein oligomers, cell signaling abnormalities and inflammation have been suggested as additional disease mechanism [<a href="#rid12">12</a>]. </p><p>The neuropathology of peroxisomal disorders is characterized by one or more of the following processes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migration and differentiation defects</strong> – Abnormal neuronal migration and differentiation vary in severity among the different disorders [<a href="#rid13">13</a>]. Migration of all neuronal classes appears to be affected, especially those destined for the outer layers of cortex.</p><p></p><p class="bulletIndent1">The abnormalities are most prominent in Zellweger spectrum disorder (ZWS) and ZWS-like disorders, including D-bifunctional protein (DBP) deficiency. ZWS and DBP are characterized by a unique combination of centrosylvian pachygyria-polymicrogyria likely responsible for seizures and global developmental delay seen in these patients [<a href="#rid14">14</a>]. In patients with neonatal adrenoleukodystrophy (NALD), which is now classified as part of the ZWS spectrum, less severe defects in cerebral migration, usually polymicrogyria, occur as diffuse, focal, or multifocal lesions that may be associated with subcortical heterotopias [<a href="#rid15">15</a>]. These also occur in DBP deficiency [<a href="#rid16">16,17</a>]. More subtle neuronal migration defects appear as heterotopic Purkinje cells [<a href="#rid18">18,19</a>]. These are usually asymptomatic.</p><p></p><p class="bulletIndent1">Neuronal migration abnormalities do not occur in all peroxisomal disorders. None have been identified in classic Refsum disease, acyl-CoA oxidase deficiency (pseudo-NALD), or X-linked adrenoleukodystrophy (X-ALD). They occur rarely in rhizomelic chondrodysplasia punctate (RCDP) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Defects in neuronal differentiation or terminal migration are common and result in dysplasia and simplification of the affected structures in ZWS. In the brainstem, they usually involve the principal nuclei of the inferior medullary olives. Less frequently, the dentate nuclei and claustra are affected. Neuronal loss may be seen in NALD [<a href="#rid21">21</a>]. The type of neuronal degeneration varies among the disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myelination abnormalities</strong> – Abnormalities in the formation or maintenance of central white matter and/or peripheral nerve myelin are frequently found in patients affected by peroxisomal disorders with neurologic involvement. Peripheral nerve involvement is less well studied than central lesions. An exception is Refsum disease, which typically has a hypertrophic (onion bulb) demyelinating neuropathy.</p><p></p><p class="bulletIndent1">Degenerative central white matter lesions consist of myelin abnormalities that can be inflammatory [<a href="#rid22">22,23</a>] or noninflammatory, and nonspecific decreases in myelin volume or staining [<a href="#rid24">24</a>]. The latter can occur with or without reactive astrocytosis. The type of neuronal degeneration varies among the disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inflammatory demyelination</strong> – Inflammatory demyelination typically occurs in X-ALD. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Neuropathology'</a>.)</p><p></p><p class="bulletIndent2">Other conditions in which inflammatory demyelination lesions occur include NALD [<a href="#rid15">15</a>], and some cases of DBP deficiency.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Noninflammatory dysmyelination</strong> – Noninflammatory dysmyelination is seen in the early stages of adrenomyeloneuropathy (AMN). The myelin appears pale, with scant interstitial macrophages that stain positive with periodic acid Schiff (PAS). No lymphocytes or reactive astrocytes are seen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other changes in myelin</strong> – Other changes in myelin include nonspecific reductions in volume or staining, with or without reactive astrocytes.</p><p></p><p class="bulletIndent2">Major post-developmental noninflammatory abnormalities may occur in specific neurons or myelinated fiber tracts. These may affect specialized sensory neurons, resulting in sensorineural hearing loss (in ZWS, alpha-methylacyl-CoA racemase [AMACR] deficiency, RCDP, and acyl CoA oxidase deficiency) or retinal pigmentary degeneration (in ZWS and AMACR deficiency). In another lesion of this type, neurons of the dorsal nuclei of Clarke and the lateral cuneate nuclei accumulate lamellar lipids that contain VLCFA. This lesion occurs only in ZWS.</p><p></p><p class="bulletIndent2">In AMN, a degenerative axonopathy involves the ascending and descending tracts of the spinal cord, especially in fasciculus gracilis and the lateral corticospinal tracts. The histologic pattern is Wallerian degeneration [<a href="#rid25">25</a>]. Mitochondrial pathology [<a href="#rid26">26</a>] and oxidative stress [<a href="#rid27">27</a>] also contribute to pathogenesis.</p><p></p><p class="bulletIndent2">Cerebellar atrophy occurs in RCDP and probably infantile Refsum disease (IRD). This appears to result from loss of Purkinje and granule cells, with focal depletion of basket cells.</p><p></p><p class="headingAnchor" id="H1638761508"><span class="h1">CLINICAL SUSPICION OF PEROXISOMAL DISORDERS</span></p><p class="headingAnchor" id="H2649537236"><span class="h2">Common clinical features</span><span class="headingEndMark"> — </span>The clinical spectrum of peroxisomal disorders is broad, ranging from severe neurologic disability presenting in the neonatal period to minor symptoms manifesting in adulthood. Despite these phenotypic variabilities, there are recognizable patterns in clinical presentation suggestive of a peroxisomal disorder. </p><p>Common clinical features that should prompt consideration of a peroxisomal disorder include [<a href="#rid5">5,28-30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Central and peripheral nervous system findings – Patients can present with variable degrees of developmental delay or cognitive impairment. Neurological examination may reveal signs of ataxia, myelopathy, and/or peripheral neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vision problems, retinopathy, cataracts, and other eye problems.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensorineural hearing loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skeletal abnormalities, such as short stature and calcific stippling on bone radiographs (chondrodysplasia punctata). </p><p></p><p class="headingAnchor" id="H921141959"><span class="h2">Patients identified through next-generation sequencing</span><span class="headingEndMark"> — </span>Increasingly, patients with peroxisomal disorders are identified through next-generation sequencing methods, including whole genome or whole exome sequencing (WGS or WES). (See  <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'Molecular genetic testing'</a>.)</p><p>In most cases when a peroxisomal disorder is identified through WGS or WES, it is appropriate to perform confirmatory biochemical testing for the specific disorder, as discussed in the following sections.</p><p class="headingAnchor" id="H670459856"><span class="h1">SPECIFIC DISORDERS</span></p><p class="headingAnchor" id="H1424070998"><span class="h2">Zellweger spectrum disorders</span><span class="headingEndMark"> — </span>Zellweger syndrome (ZS; <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F214100&amp;token=O25AxH2ZrpTPG8o%2BGEGTWP5KWy9OI76Xla3XS43k7L4vhzYkCb1Hcl2JOMk9gIsK&amp;TOPIC_ID=6147" target="_blank">MIM #214100</a>), also known as cerebrohepatorenal syndrome, is the prototype of the group of peroxisome biosynthesis disorders. It is characterized by craniofacial dysmorphisms and profound neurologic abnormalities. It is now recognized that ZS represents the most severe presentation within a larger spectrum known as the Zellweger spectrum disorders (ZSDs). </p><p>There is considerable variability within the literature regarding the classification of milder variants within the ZSD category. Some conditions included in this category were previously considered separate disorders (eg, neonatal adrenoleukodystrophy [NALD] and infantile Refsum disease [IRD]). However, since NALD and IRD are caused by the same genetic variants as ZSD (<em>PEX1</em> and <em>PEX6</em>) with a similar constellation of clinical and laboratory findings, they are now considered part of the Zellweger spectrum. As discussed below, D-bifunctional protein (DBP) deficiency and Acyl CoA oxidase-1 (ACOX1) deficiency are clinically indistinguishable from the ZSDs. (See <a class="local">'ACOX1 and DBP deficiencies'</a> below.)</p><p class="headingAnchor" id="H784240395"><span class="h3">Genetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic variants</strong> – ZSDs are caused by mutations in at least 14 different <em>PEX</em> genes which are inherited in an autosomal recessive pattern [<a href="#rid31">31</a>]. Variants in either the <em>PEX1</em> or <em>PEX6</em> genes account for approximately 75 percent of cases. <em>PEX1</em> or <em>PEX6</em> encode for ATPases that are required to import proteins from the cytosol into peroxisomes [<a href="#rid32">32</a>]. A minority of cases are caused by variants in other <em>PEX</em> genes [<a href="#rid33">33-35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype-phenotype relationship </strong>– The genotype-phenotype relationship has best been established for variants in <em>PEX1</em> [<a href="#rid36">36</a>]. Patients with frame shift mutations in <em>PEX1</em> (referred to as Maxwell variants) have fully inactive protein [<a href="#rid37">37</a>]. These patients are severely affected and do not survive beyond infancy. By contrast, patients homozygous for the G843D variant in <em>PEX1</em> have some residual protein function and are usually less severely affected. These patients present with features including developmental delay, cerebellar ataxia, peripheral neuropathy, and vision and hearing problems, but they lack craniofacial features and are not at risk for early mortality. </p><p></p><p class="headingAnchor" id="H4090477860"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>There are three general categories of ZSDs based upon the age at presentation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classical infantile ZS</strong> – Infants with classical ZS present in the newborn period with a severe phenotype characterized by a combination of characteristic findings, including [<a href="#rid30">30,38,39</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Craniofacial dysmorphisms, which may include  (<a class="graphic graphic_picture graphicRef72662" href="/z/d/graphic/72662.html" rel="external">picture 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>High forehead</p><p class="bulletIndent3"><span class="glyph">-</span>Large anterior fontanelle</p><p class="bulletIndent3"><span class="glyph">-</span>Markedly separated cranial sutures</p><p class="bulletIndent3"><span class="glyph">-</span>Hypoplastic supraorbital ridges</p><p class="bulletIndent3"><span class="glyph">-</span>Upward slant of the eyes</p><p class="bulletIndent3"><span class="glyph">-</span>Epicanthal folds</p><p class="bulletIndent3"><span class="glyph">-</span>Low and broad nasal bridge</p><p class="bulletIndent3"><span class="glyph">-</span>High-arched palate</p><p class="bulletIndent3"><span class="glyph">-</span>Deformed ear lobes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatomegaly with associated with cholestasis, cirrhosis, biliary dysgenesis, and coagulopathy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic abnormalities, including:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Profound hypotonia and weakness with absent reflexes</p><p class="bulletIndent3"><span class="glyph">-</span>Severe hearing and vision impairment</p><p class="bulletIndent3"><span class="glyph">-</span>Neonatal seizures</p><p class="bulletIndent3"><span class="glyph">-</span>Profound global developmental delay</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcific stippling of the patellae, hips, and other epiphyses (chondrodysplasia punctata), which is present in 50 to 70 percent of affected infants [<a href="#rid40">40</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cystic kidney disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pigmentary retinopathy and cataracts [<a href="#rid41">41</a>] (see  <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">"Cataract in children"</a>)</p><p></p><p class="bulletIndent1">Infants with classical ZS typically do not reach any developmental milestones and survival beyond the age of 6 to 12 months is rare [<a href="#rid40">40</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Childhood presentation</strong> – The usual onset for this category is between the first and second year of life. The disease spectrum of the childhood form is more variable compared with infantile (classical) ZS, though there is some overlap:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Developmental delay – Children may first come to clinical attention because of delayed developmental milestones and/or hypotonia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vision and hearing impairment – Progressive bilateral visual impairment and sensorineural hearing loss are consistent features. Ocular abnormalities include pigmentary retinopathy, cataract, optic nerve atrophy, glaucoma, and Bushfield spots. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver disease – Liver dysfunction with hepatomegaly, portal hypertension, prolonged jaundice, and cholestasis are frequent findings. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Facial dysmorphism are usually more subtle compared with classical ZS. </p><p></p><p class="bulletIndent1">The prognosis is variable, depending on the constellation of findings; most patients do not survive to adulthood [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescent/adult presentation</strong> – The phenotypic spectrum of ZSD presenting in adolescence and adulthood is much broader, including patients with isolated hearing loss and vision problems or isolated cerebellar ataxia [<a href="#rid43">43,44</a>]. Sensorineural hearing loss and ocular abnormalities are important clues to the diagnosis of ZDS in these patients [<a href="#rid6">6</a>]. Craniofacial dysmorphisms tend to be subtle or completely absent. Cognitive function can range from normal to severe intellectual disability. Adrenal insufficiency is common although it is asymptomatic in &gt;50 percent of affected patients [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H2315286608"><span class="h3">Neuroimaging findings</span><span class="headingEndMark"> — </span>Findings on brain magnetic resonance imaging (MRI) include cortical and white matter abnormalities [<a href="#rid46">46</a>]. In a study of six infants with ZWS, all had impaired myelination and diffusely abnormal cortical gyral patterns, consisting of microgyria and pachygyria [<a href="#rid47">47</a>]. All had germinolytic cysts in the caudothalamic groove. In mildly affected patients, MRI abnormalities may be subtle or absent [<a href="#rid48">48-50</a>].</p><p class="headingAnchor" id="H3385199448"><span class="h3">Diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial testing</strong> – When ZSD is clinically suspected, we suggest initial testing with a plasma C26:0-lysophosphatidylcholine (C26:0-LPC) level. C26:0-LPC is a more sensitive marker compared with the standard very long-chain fatty acid (VLCFA) parameters (which include C26:0 level, ratio of C26:0 to docosanoic acid [C26:0/C22:0], and ratio of C26:0 to tetracosanoic acid [C26:0/C24:0]) [<a href="#rid51">51</a>]. However, C26:0-LPC analysis is not available in all settings and standard VLCFA analysis is acceptable for initial testing if C26:0-LPC is not available. </p><p></p><p class="bulletIndent1">Elevated plasma VLCFA levels, particularly C26:0-LPC, are suggestive of ZSD, DBP deficiency, or ACOX1 deficiency [<a href="#rid52">52-56</a>]. These levels are also elevated in patients with X-ALD, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Very long-chain fatty acid levels'</a>.)</p><p></p><p class="bulletIndent1">VLCFA levels can occasionally be normal in patients with ZSD, particularly those who are older and/or mildly affected. In addition, abnormal VLCFA can be seen in patients without peroxisomal disorders who are on ketogenic diets and occasionally in those who have consumed large amounts of peanuts [<a href="#rid57">57,58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further biochemical testing</strong> – If plasma C26:0-LPC or VLCFA analysis is abnormal, additional testing is performed in the same blood sample, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Analysis of peroxisomal biomarkers in plasma (bile acid intermediates, phytanic acid, pristanic acid, pipecolic acid) </p><p class="bulletIndent2"><span class="glyph">•</span>Peroxisomal biomarkers in erythrocytes (plasmalogens)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing between ZSD and DBP or ACOX1 deficiency</strong> – Analysis of this set of peroxisomal biomarkers usually allows discrimination between ZSDs and DBP or ACOX1 deficiency. In patients with ZSD, all peroxisomal biomarkers (including erythrocyte plasmalogen levels) are abnormal whereas in patients with DBP or ACOX1 deficiency, erythrocyte plasmalogen levels are normal. ACOX1 deficiency can easily be distinguished from DBP deficiency because in ACOX1 deficiency, there is only accumulation of VLCFAs. By contrast, in DBP deficiency, there is accumulation of VLCFAs, bile acid intermediates, and pristanic and phytanic acid. A pitfall is that mildly affected patients may show a less uniform biochemical phenotype which may make it challenging to interpret the initial laboratory findings. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirming the diagnosis (genetic testing)</strong> – The combination of characteristic clinical features, abnormal VLCFA levels, and pattern of peroxisomal biomarkers in plasma and erythrocytes is sufficient to establish a preliminary diagnosis of ZSD. The diagnosis is confirmed with genetic testing. Genetic testing ensures certainty of the diagnosis and facilitates genetic counseling. Testing consists of sequencing analysis of the PEX genes. Gene panels are available that simultaneously test for multiple genetic variants that cause ZSD and other peroxisomal disorders (eg, PEX screen and others). Additional information on genetic testing, including a list of accepted laboratories providing this testing, is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=6147" target="_blank">genetic testing registry</a>.</p><p></p><p class="bulletIndent1">In some cases, additional functional studies in fibroblasts are needed to confirm the diagnosis [<a href="#rid59">59</a>]. This most commonly occurs when genetic testing identifies new mutations or variants of uncertain significance (VUS). Functional assays are performed in this setting to evaluate the biochemical significance of the variant.</p><p></p><p class="headingAnchor" id="H1691645885"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment for patients with ZSD, DBP deficiency, or ACOX1 deficiency is supportive. There are no treatments that effectively correct the underlying metabolic pathophysiology or prevent or arrest neurologic and other consequences of the disease. Appropriate counseling and support should be provided for the family/caregivers.</p><p>Treatments that have been investigated include:</p><p class="bulletIndent1"><span class="glyph">●</span>Docosahexaenoic acid (DHA) supplementation – Limited observational data suggest that DHA supplementation may improve some biochemical markers in patients with ZSD [<a href="#rid60">60</a>]; however, in a small randomized trial, DHA supplementation did not meaningfully improve clinical outcomes [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholic acid supplementation – A small uncontrolled study demonstrated that cholic acid supplementation reduced levels of toxic bile acid intermediates compared with pretreatment baseline levels in patients with ZSD [<a href="#rid62">62</a>]; however, after 21 months of treatment, there were no apparent improvements in any clinically relevant outcomes (eg, liver function, growth, survival) [<a href="#rid63">63</a>]. Nevertheless, cholic acid has been approved by the United States Food and Drug Administration for this indication [<a href="#rid64">64</a>]. It was also approved by the European Medicines Agency (EMA), but it was subsequently withdrawn from the European market [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H160898737"><span class="h2">ACOX1 and DBP deficiencies</span><span class="headingEndMark"> — </span>The clinical signs and symptoms in patients with ACOX1 deficiency or DBP deficiency are indistinguishable from those of patients with ZSD [<a href="#rid66">66,67</a>]. Indeed, the first reported cases of DBP deficiency were described as pseudo-Zellweger syndrome. (See <a class="local">'Zellweger spectrum disorders'</a> above.)</p><p>The similarities extend to neuroimaging findings, which include both developmental abnormalities (such as cortical dysplasia, peri-Sylvian polymicrogyria, delayed myelination, and germinolytic cysts) as well as late onset progressive lesions (decreasing white matter volume and bilateral ventricular dilatation and white matter lesions) [<a href="#rid29">29</a>]. (See <a class="local">'Neuroimaging findings'</a> above.)</p><p>The approach to diagnostic testing is the same as for ZSD (ie, plasma C26:0-LPC or VLCFA analysis is the initial test). Ultimately, these disorders are distinguished from ZSD on the basis of the pattern of peroxisomal biomarkers in plasma and erythrocytes and by molecular genetic testing, as discussed above. (See <a class="local">'Diagnosis'</a> above.)</p><p class="headingAnchor" id="H1871640040"><span class="h2">RCDP spectrum disorders</span><span class="headingEndMark"> — </span>Rhizomelic chondrodysplasia punctata (RCDP) type 1 (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F215100&amp;token=O25AxH2ZrpTPG8o%2BGEGTWI4F4gpXhaYEh1iAWtHTZHtpl7dL7u4gxX2wYElBuqK7&amp;TOPIC_ID=6147" target="_blank">MIM #215100</a>) is the prototype of this group of peroxisomal chondrodysplasias which now includes five distinct genetic forms. </p><p class="headingAnchor" id="H2735883270"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Five different genotypic variants of RCDP have been identified, all of which have an autosomal recessive inheritance pattern: </p><p class="bulletIndent1"><span class="glyph">●</span>RCDP type 1 – RCDP type 1 is caused by variants in the <em>PEX7</em> gene. This is the most common form of RCDP, accounting for 80 to 90 percent of cases [<a href="#rid68">68-74</a>]. <em>PEX7</em> encodes the peroxisomal type 2 targeting signal receptor that helps target cytosolic proteins to the peroxisome. <em>PEX7</em> variants can also cause Refsum disease [<a href="#rid75">75</a>]. (See <a class="local">'Refsum disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RCDP type 2 – RCDP type 2 is caused by variants in the gene that encodes glycerone-3-phosphate:acyltransferase (GNPAT). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RCDP type 3 – RCDP type 3 is caused by variants in the gene that encodes alkylglycerone-3-phosphate synthase (AGPS). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RCDP type 4 – RCDP type 4 is caused by variants in the gene that encodes fatty acyl-CoA reductase 1 (FAR1) [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RCDP type 5 – RCDP type 5 is caused by variants in <em>PEX5</em> [<a href="#rid77">77</a>].</p><p></p><p>RCDP type 1 and 5 are classified as peroxisome biogenesis disorders<strong> </strong>since <em>PEX7</em> and <em>PEX5</em> genes encode proteins involved in the proper targeting of peroxisomal proteins to peroxisomes. RCDP types 2, 3, and 4, are single peroxisomal enzyme deficiencies. In all five types of RCDP, synthesis of ether phospholipid is defective, which leads to a deficiency of plasmalogens (the dominant ether phospholipid species in mammals) in all cell types, including erythrocytes.</p><p class="headingAnchor" id="H3251607120"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>Despite the variety in the molecular defects, RCDP types 1, 2, 3, and 5 are clinically indistinguishable. The clinical features of RCDP type 4 are somewhat distinct though there are few reported cases [<a href="#rid76">76</a>]. </p><p>RCDPs present in early childhood with characteristic findings that include:</p><p class="bulletIndent1"><span class="glyph">●</span>Short stature with rhizomelia – The unique feature that distinguishes RDCPs from other peroxisomal disorders is pronounced short stature that primarily affects the proximal long bones (rhizomelia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Global developmental delay, which can be profound.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysmorphic facies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital cataracts (present in approximately 70 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ichthyosis (present in approximately 25 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Joint contractures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures. </p><p></p><p>Patients with severe forms of RCDP are generally recognized shortly after birth with typical symmetrical shortening of the proximal extremities (rhizomelia) and facial dysmorphisms. In patients with milder phenotypes, there may be only minor shortening of the proximal extremities with normal or near normal stature. Developmental delay can also be less severe. In these mildly affected patients, the diagnosis is more difficult.</p><p class="headingAnchor" id="H931700159"><span class="h3">Radiographic findings</span><span class="headingEndMark"> — </span>The characteristic radiographic finding is chondrodysplasia punctata, the stippled calcification present in long bones and vertebrae  (<a class="graphic graphic_diagnosticimage graphicRef55544" href="/z/d/graphic/55544.html" rel="external">image 1</a>). Ossification of the humerus and femur is also abnormal. Spine radiographs demonstrate an unusual coronal cleft of the vertebral bodies, which is thought to represent an embryonic arrest of bony development.</p><p class="headingAnchor" id="H2670046411"><span class="h3">Neuroimaging findings</span><span class="headingEndMark"> — </span>Reported findings on brain MRI in patients with RDCPs include [<a href="#rid78">78-80</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>White matter changes</p><p class="bulletIndent1"><span class="glyph">●</span>Pachygyria and polymicrogyria</p><p class="bulletIndent1"><span class="glyph">●</span>Ventriculomegaly</p><p class="bulletIndent1"><span class="glyph">●</span>Increased subarachnoid spaces</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellar atrophy</p><p></p><p>Children with more severe clinical disease are more likely to have abnormal MRI findings [<a href="#rid80">80</a>].</p><p>Even in the absence of white matter lesions on routine MRI, hydrogen-1 MR spectroscopy may demonstrate metabolic abnormalities consistent with the deficient plasmalogen biosynthesis [<a href="#rid78">78</a>]. </p><p class="headingAnchor" id="H926148753"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>When rhizomelic chondrodysplasia is suspected clinically, we suggest initial testing with erythrocyte plasmalogen analysis. Plasma VLCFA analysis does <strong>not</strong> play a role in the diagnosis of RCDPs since VLCFA levels are <strong>not</strong> elevated in these disorders. </p><p>RCDPs of all types and severities are associated with low levels of plasmalogens, although the deficiency may be less pronounced in mildly affected patients [<a href="#rid81">81</a>]. In RCDP types 2, 3, and 4 the deficiency of plasmalogens is the only biochemical abnormality. Patients with RCDP types 1 and 5 typically also have elevated plasma phytanic acid levels, though these levels can be in the normal range, depending on dietary intake of phytanic acid. </p><p>The combination of characteristic clinical features and low levels of erythrocyte plasmalogens is sufficient to establish a preliminary diagnosis of RCDP. The diagnosis is confirmed with genetic testing. Genetic testing ensures certainty of the diagnosis and facilitates genetic counseling. Gene panels are available that simultaneously test for multiple genetic variants that cause RDCPs and other peroxisomal disorders [<a href="#rid68">68,73</a>]. Additional information on genetic testing, including a list of accepted laboratories providing this testing, is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=6147" target="_blank">genetic testing registry</a>.</p><p class="headingAnchor" id="H2497756473"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment for patients with RCDP is supportive and may include: </p><p class="bulletIndent1"><span class="glyph">●</span>Antiseizure medication for patients with seizures (see  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of cataracts (see  <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">"Cataract in children"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Physical therapy to prevent contractures (see  <a class="medical medical_review" href="/z/d/html/118855.html" rel="external">"Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues", section on 'Physical and occupational therapy'</a>) </p><p></p><p>All patients should have routine evaluations to identify cardiac and ocular abnormalities. Orthopedic issues should be managed in collaboration with a pediatric orthopedic specialist. Regular assessment of nutritional status should also be performed. </p><p>The available evidence suggests that restriction of phytanic acid intake does not alter the disease course in RCCP [<a href="#rid74">74</a>]. This is in contrast to Refsum disease, which responds to dietary intervention. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H1174610513"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>The prognosis for patients with RCDP, particularly type 1 RCDP, is generally poor. In a report of 66 patients with RCDP (90 percent had type 1), median survival was 3.9 years [<a href="#rid74">74</a>]. The risk of early death correlated with plasmalogen levels (ie, patients with very low plasmalogen levels had shorter survival compared with those whose plasmalogen levels were only modestly decreased). </p><p class="headingAnchor" id="H3940158139"><span class="h2">Refsum disease</span><span class="headingEndMark"> — </span>Refsum disease (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F266500&amp;token=O25AxH2ZrpTPG8o%2BGEGTWEgilFtQtlkkYpLgfn5zPBU0bzjuOp9%2FpIhRV3aO%2Fnt%2F&amp;TOPIC_ID=6147" target="_blank">MIM #266500</a>) is characterized by progressive vision loss and peripheral neuropathy. A major difference from other peroxisomal disorders is that this disorder responds to dietary treatment.</p><p class="headingAnchor" id="H598136149"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Refsum disease is an autosomal recessive disorder. In most instances, Refsum disease is caused by variants in the gene <em>PHYH</em>, which encodes the enzyme phytanoyl-CoA hydroxylase (PAHX) [<a href="#rid82">82-84</a>]. A minority of individuals with Refsum disease have variants in the <em>PEX7</em> gene [<a href="#rid75">75</a>]. </p><p class="headingAnchor" id="H1686788302"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>Patients with adult Refsum disease usually present in adolescence or early adulthood. Clinical features include [<a href="#rid40">40,85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive vision loss – Impaired night vision is often the first symptom, followed by progressive loss of visual acuity due to retinitis pigmentosa (see  <a class="medical medical_review" href="/z/d/html/6905.html" rel="external">"Retinitis pigmentosa: Clinical presentation and diagnosis"</a>) </p><p class="bulletIndent1"><span class="glyph">●</span>Anosmia </p><p class="bulletIndent1"><span class="glyph">●</span>Sensorineural hearing loss </p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia</p><p class="bulletIndent1"><span class="glyph">●</span>Ichthyosis</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrhythmias (typically with onset 10 to 15 years after initial presentation)</p><p></p><p>The constellation of symptoms is variable; few patients have all of these findings [<a href="#rid85">85,86</a>]. Cognitive function is typically normal.</p><p>The clinical course is variable. Exacerbations of neurologic symptoms may occur with acute illness, fasting, rapid weight loss, surgery, or pregnancy [<a href="#rid40">40</a>].</p><p>Brain MRI abnormalities in patients with Refsum disease have been described but no clear pattern can be distinguished [<a href="#rid87">87,88</a>].</p><p class="headingAnchor" id="H1519279146"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>When Refsum disease is suspected clinically, we suggest initial testing with plasma phytanic acid level. Values in individuals with Refsum disease are typically &gt;200 micromol/L, whereas normal values are usually &lt;15 micromol/L [<a href="#rid85">85,89</a>]. </p><p>The combination of characteristic clinical features and elevated plasma phytanic acid level is sufficient to establish a preliminary diagnosis of Refsum disease. The diagnosis is confirmed with genetic testing [<a href="#rid90">90</a>]. Genetic testing ensures certainty of the diagnosis and facilitates genetic counseling.</p><p>Additional confirmatory testing may include a functional assay of PAHX activity in fibroblasts [<a href="#rid90">90</a>]. This is most helpful when genetic testing identifies a VUS. Functional assays are performed in this setting to evaluate the biochemical significance of the variant.</p><p class="headingAnchor" id="H2187019539"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The mainstay of treatment is dietary restriction to eliminate phytol-containing foods. Patients with acute severe neurologic symptoms due to elevated phytanic acid levels may require plasmapheresis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary restriction of phytanic acid intake</strong> – Foods to avoid include [<a href="#rid40">40,85</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Meat or fats from cows and other ruminating animals</p><p class="bulletIndent2"><span class="glyph">•</span>Baked goods containing animal fats</p><p class="bulletIndent2"><span class="glyph">•</span>Dairy products </p><p></p><p class="bulletIndent1">Most green vegetables are allowed since they contain low levels of free phytol [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1">The goal of dietary management is to reduce intake of phytanic acid to &lt;10 mg daily. Care should be taken to avoid rapid weight loss or fasting, since this can trigger exacerbations of neurologic symptoms [<a href="#rid92">92</a>]. </p><p></p><p class="bulletIndent1">Limited data suggest that strict reduction in dietary phytanic acid intake may improve peripheral neuropathy and ataxia [<a href="#rid93">93</a>]. In a series of 13 adult patients with Refsum disease treated with dietary therapy for ≥10 years, phytanic acid levels declined by almost 90 percent [<a href="#rid92">92</a>]. None of the participants required admission for acute symptoms of Refsum disease and/or treatment with plasmapheresis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis</strong> – For patients with severe acute neurologic symptoms, plasmapheresis can be used to rapidly lower the phytanic acid level [<a href="#rid93">93,94</a>]. Serial treatments may be necessary in some cases. Plasmapheresis efficiently removes phytanic acid associated with lipoproteins but does not efficiently deplete phytanic acid in adipose and neural tissue. Thus, it does not completely reverse neurologic abnormalities. </p><p></p><p class="headingAnchor" id="H2618563353"><span class="h2">X-linked adrenoleukodystrophy</span><span class="headingEndMark"> — </span>The features of X-linked adrenoleukodystrophy are summarized in the table  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 3</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H2881818795"><span class="h2">Primary hyperoxaluria type 1</span><span class="headingEndMark"> — </span>The primary hyperoxalurias (PH) are a group of rare inborn errors of glyoxylate metabolism resulting in enhanced production of oxalate. Type 1 PH is the most severe form. Affected patients present in infancy or early childhood with symptoms related to nephrocalcinosis, kidney stones, and chronic kidney disease. Type 1 PH is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'</a>.)</p><p class="headingAnchor" id="H1814209645"><span class="h2">Other disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACOX2 deficiency</strong> – ACOX2 deficiency is a newly identified defect that is restricted to the involvement of peroxisomes in bile acid synthesis. It has been described in only three patients, all of whom had elevated plasma levels of bile acid intermediates with otherwise normal peroxisomal parameters [<a href="#rid95">95,96</a>]. All three patients had elevated transaminases. Two patients were asymptomatic; the third patient had ataxia, cognitive impairment, and cirrhosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AMACR deficiency</strong> – There are few reported cases of AMACR (2-methylacyl-CoA racemase) deficiency in literature. In the available reports, affected patients presented with adult-onset peripheral neuropathy, retinitis pigmentosa, epilepsy, and intermittent encephalopathy [<a href="#rid97">97-103</a>]. There is one case report of an affected patient presenting in the neonatal period with fulminant liver disease presumably due to bile acid abnormalities [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BAAT deficiency –</strong> BAAT (bile acid-CoA: amino acid N-acyltransferase) deficiency<strong> </strong>has been reported in two case series [<a href="#rid105">105,106</a>]. Clinical features of affected patients included fat malabsorption, growth failure, neonatal cholestasis and liver disease (including fulminant liver failure in one patient).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other rare disorders</strong> – Other rare disorders that have been described in single case reports include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACBD5 (acyl-CoA-binding domain type 5) deficiency [<a href="#rid107">107</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Glycolate oxidase deficiency [<a href="#rid108">108,109</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>PMP70 (peroxisomal membrane protein 70) deficiency caused by a mutation in the ABCD3 gene [<a href="#rid110">110</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>SCPX (sterol carrier protein X) deficiency [<a href="#rid111">111</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Rare disorders of peroxisome division (caused by mutations in genes encoding proteins involved in peroxisome division [eg, <em>PEX11</em> beta, <em>DLP1/DNML1</em>, <em>MFF</em>, <em>GDAP1</em>]) [<a href="#rid3">3</a>]</p><p></p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSISTIC APPROACH</span></p><p class="headingAnchor" id="H1193802533"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>In general, testing for peroxisomal disorders begins with measurement of specific biochemical markers. However, there is no singular approach to the diagnosis of peroxisomal disorders since the choice of initial laboratory test(s) depends upon the constellation of clinical findings. Indeed, the long-held practice of measuring plasma very long-chain fatty acid (VLCFA) levels as an initial screening test to assess for peroxisomal disorders is not advised since VLCFAs are abnormal in only a subset of peroxisomal disorders (specifically, Zellweger spectrum disorders [ZSD], D-bifunctional protein [DBP] deficiency, acyl-CoA oxidase-1 [ACOX1] deficiency, and X-linked adrenoleukodystrophy [X-ALD]). While these represent the most common disorders, there are numerous other peroxisomal disorders that are now recognized that are not associated with elevated plasma VLCFAs.</p><p>Testing should be tailored to the specific disorder(s) suspected based upon the constellation of clinical findings  (<a class="graphic graphic_table graphicRef142994" href="/z/d/graphic/142994.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected ZSD (or ACOX1 or DBP deficiency, which are clinically indistinguishable) – Initial testing consists of measuring plasma C26:0-lysophosphatidylcholine (C26:0-LPC), if available. If C26:0-LPC is not available, standard VLCFA analysis is acceptable. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected rhizomelic chondrodysplasia punctata (RCDP) disorders – Initial testing consists of erythrocyte plasmalogen analysis. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected Refsum disease – Initial testing consists of plasma phytanic acid levels. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected X-ALD – Initial testing consists of measuring plasma C26:0-LPC or VLCFA levels  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 3</a>). Laboratory testing for X-ALD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hyperoxaluria type 1 (PH1) – Initial testing consists of measuring urinary oxalate. Laboratory testing for PH1 is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Metabolic testing'</a>.) </p><p></p><p>If results of initial biochemical tests are abnormal, confirmatory genetic testing is generally required. Gene panels are available that simultaneously test for multiple genetic variants that cause peroxisomal disorders. Information on genetic testing, including a list of accepted laboratories providing this testing, is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=6147" target="_blank">genetic testing registry</a>. Additional confirmatory testing with functional assays using fibroblasts can sometimes be useful in the diagnostic evaluation (eg, if genetic testing identifies a variant of uncertain significance) [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H15"><span class="h2">Prenatal diagnosis</span><span class="headingEndMark"> — </span>Prenatal testing for peroxisomal disorders is available for subsequent pregnancies of individuals with affected children or other positive family history. Prenatal diagnostic methods have generally shifted from biochemical to molecular-based methods. Using assisted reproductive technology, preimplantation diagnosis can be achieved in embryos using multiple displacement amplification [<a href="#rid112">112</a>]. Issues related to preimplantation genetic testing<strong> </strong>are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p>Antenatal diagnosis is sometimes made by ultrasonography. In one report, increased nuchal translucency and decreased fetal movements suggested the diagnosis of Zellweger syndrome in a fetus at risk [<a href="#rid113">113</a>]. The diagnosis was confirmed by metabolic studies on cells obtained by chorionic villus sampling. In another report, RCDP was identified in a fetus with no family history based on the findings of severe limb shortening, premature ossification, and stippling of multiple epiphyses [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H377593252"><span class="h2">Newborn screening</span><span class="headingEndMark"> — </span>Newborn screening for X-ALD is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Newborn screening'</a>.)</p><p>The screening approach used for X-ALD, which involves measurement of VLCFAs, may also detect other peroxisomal disorders, including ZSD.</p><p class="headingAnchor" id="H53"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiology</strong> – Peroxisomes are subcellular organelles that are present in all cells except erythrocytes. They host numerous catabolic and anabolic pathways that are essential to normal cellular metabolism. Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism that result in impairment of peroxisome function. In most cases, this results in neurologic dysfunction of varying extent. (See <a class="local">'Pathophysiology'</a> above and <a class="local">'Neuropathology'</a> above.)</p><p></p><p class="bulletIndent1">Peroxisomal disorders can be caused by defects in the biogenesis of peroxisomes or by deficiencies of individual peroxisomal enzymes  (<a class="graphic graphic_table graphicRef74261" href="/z/d/graphic/74261.html" rel="external">table 1</a>). A rare third category is disorders of peroxisome division. (See <a class="local">'Classification by mechanism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical classification</strong> – Clinically, the peroxisomal disorders can be subdivided into six main groups, including  (<a class="graphic graphic_table graphicRef142994" href="/z/d/graphic/142994.html" rel="external">table 2</a>) (see <a class="local">'Clinical classification'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cerebrohepatorenal syndromes</strong> – This category includes disorders that are characterized by variable degrees of liver and kidney involvement in conjunction with neurologic abnormalities, vision and hearing impairment, and craniofacial dysmorphisms. These include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Zellweger spectrum disorders (see <a class="local">'Zellweger spectrum disorders'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Acyl CoA oxidase-1 (ACOX1) deficiency (see <a class="local">'ACOX1 and DBP deficiencies'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>D-bifunctional protein (DBP) deficiency (see <a class="local">'ACOX1 and DBP deficiencies'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rhizomelic chondrodysplasias</strong> – This category includes rhizomelic chondrodysplasia punctata (RCDP) types 1 to 5. The unique feature that distinguishes RDCPs from other peroxisomal disorders is pronounced short stature that primarily affects the proximal long bones (rhizomelia). Other clinical features include developmental delay, dysmorphic facies, congenital cataracts, ichthyosis, and joint contractures. (See <a class="local">'RCDP spectrum disorders'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refsum disease</strong> – Refsum disease is characterized by progressive vision loss and peripheral neuropathy. Unlike many other peroxisomal disorders, which often present in infancy or early childhood, Refsum disease typically presents in adolescence or early adulthood. Another distinction is that Refsum disease responds to dietary treatment. (See <a class="local">'Refsum disease'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>X-linked adrenoleukodystrophy (ALD) </strong>– The clinical spectrum of X-ALD is variable, as summarized in the table  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 3</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary hyperoxaluria type 1 (PH1)</strong> – PH1 is characterized by recurrent kidney stones and chronic kidney disease. It is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other rare disorders</strong> – The fifth category consists of a group of rare disorders with variable features. (See <a class="local">'Other disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical spectrum of peroxisomal disorders is broad, ranging from severe neurologic disability presenting in the neonatal period to minor symptoms manifesting in adulthood. Common clinical features that should prompt consideration of a peroxisomal disorder include (see <a class="local">'Common clinical features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central and peripheral nervous system findings</p><p class="bulletIndent2"><span class="glyph">•</span>Vision problems, retinopathy, cataracts, and other eye problems</p><p class="bulletIndent2"><span class="glyph">•</span>Sensorineural hearing loss</p><p class="bulletIndent2"><span class="glyph">•</span>Liver disease</p><p class="bulletIndent2"><span class="glyph">•</span>Adrenal insufficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Skeletal abnormalities, such as short stature and calcific stippling on bone radiographs (chondrodysplasia punctata) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic approach</strong> – In general, testing for peroxisomal disorders begins with measurement of biochemical markers. Testing is tailored to the specific disorder(s) suspected based upon the constellation of clinical findings  (<a class="graphic graphic_table graphicRef142994" href="/z/d/graphic/142994.html" rel="external">table 2</a>) (see <a class="local">'Diagnosistic approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected ZSD (or ACOX1 or DBP deficiency, which are clinically indistinguishable) – Initial testing consists of measuring plasma C26:0-lysophosphatidylcholine (C26:0-LPC), where available, or standard very long-chain fatty acid (VLCFA) analysis if C26:0-LPC testing is not available. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected RCDP disorders – Initial testing consists of erythrocyte plasmalogen analysis. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected Refsum disease – Initial testing consists of plasma phytanic acid levels. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected X-ALD – Initial testing consists of measuring plasma C26:0-LYSOPC, where available, or standard VLCFA analysis if C26:0-LYSOPC testing is not available  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary hyperoxaluria type 1 (PH1) – Initial testing consists of measuring urinary oxalate. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Metabolic testing'</a>.) </p><p></p><p class="bulletIndent1">If the initial biochemical test is abnormal, confirmatory genetic testing is generally required. Additional confirmatory testing with functional assays using fibroblasts can sometimes be useful in the diagnostic evaluation (eg, if genetic testing identifies a variant of uncertain significance). </p><p></p><p class="headingAnchor" id="H3417505799"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Alan K Percy, MD, and Raphael Schiffman, MD, MHSc, FAAN, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab 2016; 117:313.</a></li><li><a class="nounderline abstract_t">Klouwer FC, Berendse K, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical overview and management approach. Orphanet J Rare Dis 2015; 10:151.</a></li><li><a class="nounderline abstract_t">Wanders RJA, Baes M, Ribeiro D, et al. The physiological functions of human peroxisomes. Physiol Rev 2023; 103:957.</a></li><li><a class="nounderline abstract_t">Waterham HR, Ferdinandusse S, Wanders RJ. Human disorders of peroxisome metabolism and biogenesis. Biochim Biophys Acta 2016; 1863:922.</a></li><li><a class="nounderline abstract_t">Baumgartner MR, Poll-The BT, Verhoeven NM, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol 1998; 44:720.</a></li><li class="breakAll">Gilles L, Adams R, Kolony E. The neurology of neonatal hereditary metabolic diseases. In: Neurology of Hereditary Metabolic Diseases of Children, 2nd ed, McGraw Hill, New York 1996.</li><li class="breakAll">Thomas JA, Greene CL, Cohn RM. Lysosomal storage and peroxisomal disorders presenting in the newborn. In: Avery's Diseases of the Newborn, 7th ed, Taeusch HW, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.275.</li><li><a class="nounderline abstract_t">Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 2006; 75:295.</a></li><li><a class="nounderline abstract_t">Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J Lipid Res 2010; 51:2863.</a></li><li><a class="nounderline abstract_t">Wanders RJ. Metabolic functions of peroxisomes in health and disease. Biochimie 2014; 98:36.</a></li><li><a class="nounderline abstract_t">Wanders RJ, Waterham HR, Ferdinandusse S. Metabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic Reticulum. Front Cell Dev Biol 2015; 3:83.</a></li><li><a class="nounderline abstract_t">Crane DI. Revisiting the neuropathogenesis of Zellweger syndrome. Neurochem Int 2014; 69:1.</a></li><li><a class="nounderline abstract_t">Powers JM. Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders. J Mol Neurosci 2001; 16:285.</a></li><li><a class="nounderline abstract_t">Volpe JJ, Adams RD. Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. Acta Neuropathol 1972; 20:175.</a></li><li><a class="nounderline abstract_t">Kelley RI, Datta NS, Dobyns WB, et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 1986; 23:869.</a></li><li><a class="nounderline abstract_t">Powers JM. The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol 1995; 54:710.</a></li><li><a class="nounderline abstract_t">Kaufmann WE, Theda C, Naidu S, et al. Neuronal migration abnormality in peroxisomal bifunctional enzyme defect. Ann Neurol 1996; 39:268.</a></li><li><a class="nounderline abstract_t">Dimmick JE, Applegarth DA. Pathology of peroxisomal disorders. Perspect Pediatr Pathol 1993; 17:45.</a></li><li class="breakAll">Powers J. Peroxisomal diseases. In: Pediatric Neuropathology, Williams and Wilkins, Baltimore, MD 1995.</li><li><a class="nounderline abstract_t">YAKOVAC WC. Calcareous chondropathies in the newborn infant. AMA Arch Pathol 1954; 57:62.</a></li><li><a class="nounderline abstract_t">Jaffe R, Crumrine P, Hashida Y, Moser HW. Neonatal adrenoleukodystrophy: clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females. Am J Pathol 1982; 108:100.</a></li><li><a class="nounderline abstract_t">Griffin DE, Moser HW, Mendoza Q, et al. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol 1985; 18:660.</a></li><li><a class="nounderline abstract_t">Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51:630.</a></li><li><a class="nounderline abstract_t">Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol 1998; 8:101.</a></li><li><a class="nounderline abstract_t">Powers JM, DeCiero DP, Ito M, et al. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000; 59:89.</a></li><li><a class="nounderline abstract_t">Powers JM, DeCiero DP, Cox C, et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 2001; 60:493.</a></li><li><a class="nounderline abstract_t">Powers JM, Pei Z, Heinzer AK, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005; 64:1067.</a></li><li><a class="nounderline abstract_t">Theil AC, Schutgens RB, Wanders RJ, Heymans HS. Clinical recognition of patients affected by a peroxisomal disorder: a retrospective study in 40 patients. Eur J Pediatr 1992; 151:117.</a></li><li><a class="nounderline abstract_t">Klouwer FC, Huffnagel IC, Ferdinandusse S, et al. Clinical and Biochemical Pitfalls in the Diagnosis of Peroxisomal Disorders. Neuropediatrics 2016; 47:205.</a></li><li><a class="nounderline abstract_t">Bose M, Yergeau C, D'Souza Y, et al. Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta-Analysis and Medical Chart Review. Cells 2022; 11.</a></li><li><a class="nounderline abstract_t">Ebberink MS, Mooijer PA, Gootjes J, et al. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat 2011; 32:59.</a></li><li><a class="nounderline abstract_t">Geisbrecht BV, Collins CS, Reuber BE, Gould SJ. Disruption of a PEX1-PEX6 interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. Proc Natl Acad Sci U S A 1998; 95:8630.</a></li><li><a class="nounderline abstract_t">Turner CL, Bunyan DJ, Thomas NS, et al. Zellweger syndrome resulting from maternal isodisomy of chromosome 1. Am J Med Genet A 2007; 143A:2172.</a></li><li><a class="nounderline abstract_t">Falkenberg KD, Braverman NE, Moser AB, et al. Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder. Am J Hum Genet 2017; 101:965.</a></li><li><a class="nounderline abstract_t">Matsui S, Funahashi M, Honda A, Shimozawa N. Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene. Brain Dev 2013; 35:842.</a></li><li><a class="nounderline abstract_t">Preuss N, Brosius U, Biermanns M, et al. PEX1 mutations in complementation group 1 of Zellweger spectrum patients correlate with severity of disease. Pediatr Res 2002; 51:706.</a></li><li><a class="nounderline abstract_t">Maxwell MA, Nelson PV, Chin SJ, et al. A common PEX1 frameshift mutation in patients with disorders of peroxisome biogenesis correlates with the severe Zellweger syndrome phenotype. Hum Genet 1999; 105:38.</a></li><li><a class="nounderline abstract_t">Smith DW, Opitz JM, Inhorn SL. A syndrome of multiple developmental defects including polycystic kidneys and intrahepatic biliary dysgenesis in 2 siblings. J Pediatr 1965; 67:617.</a></li><li><a class="nounderline abstract_t">Passarge E, McAdams AJ. Cerebro-hepato-renal syndrome. A newly recognized hereditary disorder of multiple congenital defects, including sudanophilic leukodystrophy,  cirrhosis of the liver, and polycystic kidneys. J Pediatr 1967; 71:691.</a></li><li><a class="nounderline abstract_t">Percy AK, Rutledge SL. Adrenoleukodystrophy and related disorders. Ment Retard Dev Disabil Res Rev 2001; 7:179.</a></li><li class="breakAll">Volpe JJ. Degenerative diseases of the newborn. In: Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001. p.599.</li><li><a class="nounderline abstract_t">Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inherit Metab Dis 2007; 30:193.</a></li><li><a class="nounderline abstract_t">Régal L, Ebberink MS, Goemans N, et al. Mutations in PEX10 are a cause of autosomal recessive ataxia. Ann Neurol 2010; 68:259.</a></li><li><a class="nounderline abstract_t">Sevin C, Ferdinandusse S, Waterham HR, et al. Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J Rare Dis 2011; 6:8.</a></li><li><a class="nounderline abstract_t">Berendse K, Engelen M, Linthorst GE, et al. High prevalence of primary adrenal insufficiency in Zellweger spectrum disorders. Orphanet J Rare Dis 2014; 9:133.</a></li><li><a class="nounderline abstract_t">van der Knaap MS, Wassmer E, Wolf NI, et al. MRI as diagnostic tool in early-onset peroxisomal disorders. Neurology 2012; 78:1304.</a></li><li><a class="nounderline abstract_t">Barkovich AJ, Peck WW. MR of Zellweger syndrome. AJNR Am J Neuroradiol 1997; 18:1163.</a></li><li><a class="nounderline abstract_t">Barth PG, Gootjes J, Bode H, et al. Late onset white matter disease in peroxisome biogenesis disorder. Neurology 2001; 57:1949.</a></li><li><a class="nounderline abstract_t">Barth PG, Majoie CB, Gootjes J, et al. Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival. Neurology 2004; 62:439.</a></li><li><a class="nounderline abstract_t">Poll-The BT, Gärtner J. Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta 2012; 1822:1421.</a></li><li><a class="nounderline abstract_t">Klouwer FCC, Ferdinandusse S, van Lenthe H, et al. Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders. J Inherit Metab Dis 2017; 40:875.</a></li><li><a class="nounderline abstract_t">Rosewich H, Waterham HR, Wanders RJ, et al. Pitfall in metabolic screening in a patient with fatal peroxisomal beta-oxidation defect. Neuropediatrics 2006; 37:95.</a></li><li><a class="nounderline abstract_t">Pierce SB, Walsh T, Chisholm KM, et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum Genet 2010; 87:282.</a></li><li><a class="nounderline abstract_t">McMillan HJ, Worthylake T, Schwartzentruber J, et al. Specific combination of compound heterozygous mutations in 17β-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet J Rare Dis 2012; 7:90.</a></li><li><a class="nounderline abstract_t">Lines MA, Jobling R, Brady L, et al. Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. Neurology 2014; 82:963.</a></li><li><a class="nounderline abstract_t">Berendse K, Engelen M, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood. J Inherit Metab Dis 2016; 39:93.</a></li><li><a class="nounderline abstract_t">Lam C, Wong D, Cederbaum S, et al. Peanut consumption increases levels of plasma very long chain fatty acids in humans. Mol Genet Metab 2012; 107:620.</a></li><li><a class="nounderline abstract_t">Theda C, Woody RC, Naidu S, et al. Increased very long chain fatty acids in patients on a ketogenic diet: a cause of diagnostic confusion. J Pediatr 1993; 122:724.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Ebberink MS, Vaz FM, et al. The important role of biochemical and functional studies in the diagnostics of peroxisomal disorders. J Inherit Metab Dis 2016; 39:531.</a></li><li><a class="nounderline abstract_t">Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001; 16:309.</a></li><li><a class="nounderline abstract_t">Paker AM, Sunness JS, Brereton NH, et al. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology 2010; 75:826.</a></li><li><a class="nounderline abstract_t">Berendse K, Klouwer FC, Koot BG, et al. Cholic acid therapy in Zellweger spectrum disorders. J Inherit Metab Dis 2016; 39:859.</a></li><li><a class="nounderline abstract_t">Klouwer FCC, Koot BGP, Berendse K, et al. The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy. J Inherit Metab Dis 2019; 42:303.</a></li><li class="breakAll">CHOLBAM prescribing information, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205750lbl.pdf (Accessed on March 20, 2015).</li><li class="breakAll">Kolbam EMA withdrawal https://www.ema.europa.eu/en/medicines/human/EPAR/kolbam (Accessed on July 17, 2020).</li><li><a class="nounderline abstract_t">Ferdinandusse S, Denis S, Hogenhout EM, et al. Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat 2007; 28:904.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Denis S, Mooyer PA, et al. Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol 2006; 59:92.</a></li><li><a class="nounderline abstract_t">Braverman N, Chen L, Lin P, et al. Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Hum Mutat 2002; 20:284.</a></li><li><a class="nounderline abstract_t">Motley AM, Hettema EH, Hogenhout EM, et al. Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor. Nat Genet 1997; 15:377.</a></li><li><a class="nounderline abstract_t">Braverman N, Steel G, Obie C, et al. Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nat Genet 1997; 15:369.</a></li><li><a class="nounderline abstract_t">Purdue PE, Zhang JW, Skoneczny M, Lazarow PB. Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor. Nat Genet 1997; 15:381.</a></li><li><a class="nounderline abstract_t">Ofman R, Hettema EH, Hogenhout EM, et al. Acyl-CoA:dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet 1998; 7:847.</a></li><li><a class="nounderline abstract_t">Motley AM, Brites P, Gerez L, et al. Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1. Am J Hum Genet 2002; 70:612.</a></li><li><a class="nounderline abstract_t">Duker AL, Niiler T, Kinderman D, et al. Rhizomelic chondrodysplasia punctata morbidity and mortality, an update. Am J Med Genet A 2020; 182:579.</a></li><li><a class="nounderline abstract_t">van den Brink DM, Brites P, Haasjes J, et al. Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet 2003; 72:471.</a></li><li><a class="nounderline abstract_t">Buchert R, Tawamie H, Smith C, et al. A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. Am J Hum Genet 2014; 95:602.</a></li><li><a class="nounderline abstract_t">Barøy T, Koster J, Strømme P, et al. A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. Hum Mol Genet 2015; 24:5845.</a></li><li><a class="nounderline abstract_t">Viola A, Confort-Gouny S, Ranjeva JP, et al. MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata. AJNR Am J Neuroradiol 2002; 23:480.</a></li><li><a class="nounderline abstract_t">Goh S. Neuroimaging features in a neonate with rhizomelic chondrodysplasia punctata. Pediatr Neurol 2007; 37:382.</a></li><li><a class="nounderline abstract_t">Bams-Mengerink AM, Majoie CB, Duran M, et al. MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 2006; 66:798.</a></li><li><a class="nounderline abstract_t">Smeitink JA, Beemer FA, Espeel M, et al. Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis. J Inherit Metab Dis 1992; 15:377.</a></li><li><a class="nounderline abstract_t">Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997; 17:190.</a></li><li><a class="nounderline abstract_t">Mihalik SJ, Morrell JC, Kim D, et al. Identification of PAHX, a Refsum disease gene. Nat Genet 1997; 17:185.</a></li><li><a class="nounderline abstract_t">Jansen GA, Hogenhout EM, Ferdinandusse S, et al. Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease. Hum Mol Genet 2000; 9:1195.</a></li><li><a class="nounderline abstract_t">Wierzbicki AS, Lloyd MD, Schofield CJ, et al. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem 2002; 80:727.</a></li><li><a class="nounderline abstract_t">Wierzbicki AS, Mitchell J, Lambert-Hammill M, et al. Identification of genetic heterogeneity in Refsum's disease. Eur J Hum Genet 2000; 8:649.</a></li><li><a class="nounderline abstract_t">Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006; 1:40.</a></li><li><a class="nounderline abstract_t">Bompaire F, Marcaud V, Trionnaire EL, et al. Refsum Disease Presenting with a Late-Onset Leukodystrophy. JIMD Rep 2015; 19:7.</a></li><li><a class="nounderline abstract_t">Verhoeven NM, Kulik W, van den Heuvel CM, Jakobs C. Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatography--mass spectrometry. J Inherit Metab Dis 1995; 18 Suppl 1:45.</a></li><li><a class="nounderline abstract_t">Jansen GA, Waterham HR, Wanders RJ. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat 2004; 23:209.</a></li><li><a class="nounderline abstract_t">Brown PJ, Mei G, Gibberd FB, et al. Diet and Refsum's disease: The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease. J Hum Nutr Diet 1993; 6:295.</a></li><li><a class="nounderline abstract_t">Baldwin EJ, Gibberd FB, Harley C, et al. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry 2010; 81:954.</a></li><li><a class="nounderline abstract_t">Hungerbühler JP, Meier C, Rousselle L, et al. Refsum's disease: management by diet and plasmapheresis. Eur Neurol 1985; 24:153.</a></li><li><a class="nounderline abstract_t">Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry 1991; 54:614.</a></li><li><a class="nounderline abstract_t">Vilarinho S, Sari S, Mazzacuva F, et al. ACOX2 deficiency: A disorder of bile acid synthesis with transaminase elevation, liver fibrosis, ataxia, and cognitive impairment. Proc Natl Acad Sci U S A 2016; 113:11289.</a></li><li><a class="nounderline abstract_t">Monte MJ, Alonso-Peña M, Briz O, et al. ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. J Hepatol 2017; 66:581.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Denis S, Clayton PT, et al. Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 2000; 24:188.</a></li><li><a class="nounderline abstract_t">Clarke CE, Alger S, Preece MA, et al. Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency. Neurology 2004; 63:188.</a></li><li><a class="nounderline abstract_t">Thompson SA, Calvin J, Hogg S, et al. Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency. J Neurol Neurosurg Psychiatry 2008; 79:448.</a></li><li><a class="nounderline abstract_t">Kapina V, Sedel F, Truffert A, et al. Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency. Neurology 2010; 75:1300.</a></li><li><a class="nounderline abstract_t">Smith EH, Gavrilov DK, Oglesbee D, et al. An adult onset case of alpha-methyl-acyl-CoA racemase deficiency. J Inherit Metab Dis 2010; 33 Suppl 3:S349.</a></li><li><a class="nounderline abstract_t">Dick D, Horvath R, Chinnery PF. AMACR mutations cause late-onset autosomal recessive cerebellar ataxia. Neurology 2011; 76:1768.</a></li><li><a class="nounderline abstract_t">Stewart MW, Vavra MW, Whaley NR. FUNDUS FINDINGS IN A PATIENT WITH α-METHLYACYL-COA RACEMASE DEFICIENCY. Retin Cases Brief Rep 2011; 5:262.</a></li><li><a class="nounderline abstract_t">Setchell KD, Heubi JE, Bove KE, et al. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 2003; 124:217.</a></li><li><a class="nounderline abstract_t">Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin Liver Dis 2007; 27:282.</a></li><li><a class="nounderline abstract_t">Carlton VE, Harris BZ, Puffenberger EG, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet 2003; 34:91.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Falkenberg KD, Koster J, et al. ACBD5 deficiency causes a defect in peroxisomal very long-chain fatty acid metabolism. J Med Genet 2017; 54:330.</a></li><li><a class="nounderline abstract_t">Frishberg Y, Zeharia A, Lyakhovetsky R, et al. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet 2014; 51:526.</a></li><li><a class="nounderline abstract_t">Clifford-Mobley O, Rumsby G, Kanodia S, et al. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria. Pediatr Nephrol 2017; 32:2159.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Jimenez-Sanchez G, Koster J, et al. A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. Hum Mol Genet 2015; 24:361.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Kostopoulos P, Denis S, et al. Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. Am J Hum Genet 2006; 78:1046.</a></li><li><a class="nounderline abstract_t">Lledó B, Bernabeu R, Ten J, et al. Preimplantation genetic diagnosis of X-linked adrenoleukodystrophy with gender determination using multiple displacement amplification. Fertil Steril 2007; 88:1327.</a></li><li><a class="nounderline abstract_t">Johnson JM, Babul-Hirji R, Chitayat D. First-trimester increased nuchal translucency and fetal hypokinesia associated with Zellweger syndrome. Ultrasound Obstet Gynecol 2001; 17:344.</a></li><li><a class="nounderline abstract_t">Hertzberg BS, Kliewer MA, Decker M, et al. Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. J Ultrasound Med 1999; 18:715.</a></li></ol></div><div id="topicVersionRevision">Topic 6147 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26750748" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26627182" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Zellweger spectrum disorders: clinical overview and management approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35951481" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The physiological functions of human peroxisomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26611709" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human disorders of peroxisome metabolism and biogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818927" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical approach to inherited peroxisomal disorders: a series of 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818927" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical approach to inherited peroxisomal disorders: a series of 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818927" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical approach to inherited peroxisomal disorders: a series of 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16756494" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Biochemistry of mammalian peroxisomes revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558530" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24012550" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Metabolic functions of peroxisomes in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858947" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Metabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic Reticulum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24607700" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Revisiting the neuropathogenesis of Zellweger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11478383" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5043999" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3515938" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666061" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The pathology of peroxisomal disorders with pathogenetic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8967760" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neuronal migration abnormality in peroxisomal bifunctional enzyme defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316527" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pathology of peroxisomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316527" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pathology of peroxisomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13103928" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Calcareous chondropathies in the newborn infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091298" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neonatal adrenoleukodystrophy: clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3909937" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1362438" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458170" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749098" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11379824" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319717" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adreno-leukodystrophy: oxidative stress of mice and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1371465" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical recognition of patients affected by a peroxisomal disorder: a retrospective study in 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27089543" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical and Biochemical Pitfalls in the Diagnosis of Peroxisomal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35741019" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta-Analysis and Medical Chart Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21031596" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9671729" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Disruption of a PEX1-PEX6 interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702006" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Zellweger syndrome resulting from maternal isodisomy of chromosome 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29220678" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23245813" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032265" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : PEX1 mutations in complementation group 1 of Zellweger spectrum patients correlate with severity of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480353" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A common PEX1 frameshift mutation in patients with disorders of peroxisome biogenesis correlates with the severe Zellweger syndrome phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5832556" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A syndrome of multiple developmental defects including polycystic kidneys and intrahepatic biliary dysgenesis in 2 siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4383264" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cerebro-hepato-renal syndrome. A newly recognized hereditary disorder of multiple congenital defects, including sudanophilic leukodystrophy,  cirrhosis of the liver, and polycystic kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553934" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adrenoleukodystrophy and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553934" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adrenoleukodystrophy and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17347916" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular and clinical aspects of peroxisomal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695019" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mutations in PEX10 are a cause of autosomal recessive ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392394" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25179809" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : High prevalence of primary adrenal insufficiency in Zellweger spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459681" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : MRI as diagnostic tool in early-onset peroxisomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9194444" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : MR of Zellweger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11769739" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Late onset white matter disease in peroxisome biogenesis disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872027" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483868" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28677031" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773508" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pitfall in metabolic screening in a patient with fatal peroxisomal beta-oxidation defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20673864" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23181892" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Specific combination of compound heterozygous mutations in 17β-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553428" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287655" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864056" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Peanut consumption increases levels of plasma very long chain fatty acids in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496750" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Increased very long chain fatty acids in patients on a ketogenic diet: a cause of diagnostic confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26943801" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The important role of biochemical and functional studies in the diagnostics of peroxisomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11478386" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Restoring the DHA levels in the brains of Zellweger patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20805528" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27469511" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cholic acid therapy in Zellweger spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793331" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793331" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793331" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17458872" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278854" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical and biochemical spectrum of D-bifunctional protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12325024" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090382" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090381" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090383" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9536089" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Acyl-CoA:dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781871" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31769196" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Rhizomelic chondrodysplasia punctata morbidity and mortality, an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522768" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Identification of PEX7 as the second gene involved in Refsum disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439727" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220973" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11901023" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950430" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Neuroimaging features in a neonate with rhizomelic chondrodysplasia punctata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567694" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405474" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326940" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326939" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Identification of PAHX, a Refsum disease gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767344" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948235" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951529" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Identification of genetic heterogeneity in Refsum's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032466" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25604618" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Refsum Disease Presenting with a Late-Onset Leukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9053555" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatography--mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974078" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Diet and Refsum's disease: The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547622" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2581787" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Refsum's disease: management by diet and plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716665" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27647924" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : ACOX2 deficiency: A disorder of bile acid synthesis with transaminase elevation, liver fibrosis, ataxia, and cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27884763" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655068" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249642" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032455" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921516" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20821052" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : An adult onset case of alpha-methyl-acyl-CoA racemase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576695" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : AMACR mutations cause late-onset autosomal recessive cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25390181" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : FUNDUS FINDINGS IN A PATIENT WITHα-METHLYACYL-COA RACEMASE DEFICIENCY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12512044" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17682975" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Inborn errors of bile acid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704386" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27799409" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : ACBD5 deficiency causes a defect in peroxisomal very long-chain fatty acid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996905" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28752386" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168382" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685654" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498713" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Preimplantation genetic diagnosis of X-linked adrenoleukodystrophy with gender determination using multiple displacement amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11339194" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : First-trimester increased nuchal translucency and fetal hypokinesia associated with Zellweger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511306" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
